Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02875392 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

OTHER: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
OTHER: placebo pills

Sponsor

Taipei Medical University WanFang Hospital